

To: (10)(2e) 2 (10)(2e) @minvws.nl
Cc: (10)(2e) (10)(2e) @minvws.nl; (10)(2e) (10)(2e) @minbuza.nl; (10)(2e) 4 (10)(2e) (10)(2e) (10)(2e) @minvws.nl; (10)(2e) (10)(2e) @minvws.nl
From: (10)(2e)
Sent: Fri 9/25/2020 4:11:14 PM
Subject: US\$35 billion price tag to end the acute phase of the pandemic
Received: Fri 9/25/2020 4:11:15 PM

(10)(2e)

Nog eentje voor het weekend.

(10)(2a) heeft een nieuwe berekening gemaakt van de totale kosten voor het bestrijden van de acute fase van de COVID-uitbraak.

Ze ramen (of misschien wel framen) nu 35 miljard USD. Met allerlei pledge-ronden is nu ongeveer 16 miljard opgehaald. Nog een kleine 20 te gaan.

Dit betekent dat de komende periode er nog een grote vraag komt voor internationale solidariteit.

Kyriakides nam hier laatst al een voorschot op door te roepen om onorthodoxe maatregelen en ideeën:
https://ec.europa.eu/commission/commissioners/2019-2024/kyriakides/announcements/remarks-commissioner-kyriakides-during-g20-joint-meeting-finance-and-health-ministers_en

Met onze huidige bijdragen aan de aan de internationale gremia (zie hieronder) komen we de komende periode niet weg.

Denk dat we met onze BZ/OS collega's een stevige strategie moeten gaan bedenken.

Ook intern VWS moeten de geesten gaan rijp maken. Wellicht door komende MinStaf en DGV-mt deze nieuwe cijfers te communiceren.

Die zullen tijdens de UNGA-bijeenkomst ook in de media gaan rondzingen.

Groot,
 (10)(2e)

Onze NL teller staat nu op:

1^e tranche COVID /BZ /VWS
 CEPI
 GAVI algemeen
 Via EU

(10)(2b)

Nog nader te bepalen:
 2^e tranche BZ Covax/FIND
 VWS tbv vaccins

(10)(2b)

Van: WHO Media <(10)(2e)@campaign.who.int>
Verzonden: 25 September 2020 17:43
Aan: (10)(2e) <(10)(2e)@minvws.nl>
Onderwerp: MEDIA ADVISORY: US\$35 billion price tag to end the acute phase of the pandemic

No images? [Click here](#)



Friday, 25 September 2020

MEDIA ADVISORY**US\$35 billion price tag to end the acute phase of the pandemic***Partners lay out investment needed to speed up access to COVID-19 diagnostics, vaccines and treatments*

[An economic investment case & financing requirements September 2020 - December 2021](#)

[Status Report & Plan September 2020 - December 2021](#)



The ACT-Accelerator is the only global initiative offering a solution to speed up the end of the COVID-19 pandemic. Launched on 24 April 2020, it combines public and private sector expertise and institutions from around the world to accelerate the development, regulatory approval, scale-up, delivery and equitable allocation of COVID-19 tests, treatments and vaccines.

The ACT-Accelerator needs US\$35 billion to meet the goal of developing new tools and producing and delivering 2 billion vaccine doses, 245 million treatments and 500 million diagnostic tests over the next year.

With the largest portfolio of COVID-19 tools in the world, investing in the ACT-Accelerator increases the probability of being able to access the “winning candidate” and hedges the risk that countries that have already entered individual bilateral agreements end up with products that are not viable.

The economic rationale for investment is clear:

- The global economy is expected to contract by US\$7 trillion in 2020 as a result of the pandemic. ACT-Accelerator’s financing gap is US\$35 billion. Fully financing the ACT-Accelerator to help shorten the duration of the crisis would pay back this investment in less than 36 hours once global mobility and trade are restored.
 - ACT-Accelerator total funding needs represent less than 1% of what G20 governments have already committed to domestic economic stimulus packages. While many countries have made significant investments in domestic R&D and on domestic economic stimulus packages, these investments will not on their own address severe COVID-19 disease, the root cause of the crisis, and the key to restarting all aspects of their economies.
- A lack of innovation for and sufficient access to effective tests, treatments and vaccines would hold up the recovery for all countries.

In just 5 months, the ACT-Accelerator has made significant progress, as evidenced by the status report, published today:

- The Diagnostics pillar is evaluating more than 50 diagnostic tests
- The Therapeutics pillar is analysing 1,700+ clinical trials for promising treatments and has secured Dexamethasone for up to 4.5 million patients in lower-income countries
- COVAX vaccine facility - the largest and most varied portfolio of COVID-19 vaccines globally - currently contains 9 vaccine candidates and a total of 156 economies, representing nearly two-thirds of the global population, are now committed to or eligible to receive vaccines through the Facility

Leaders will next meet on 30th September at a high-level side event during the United

Nations General Assembly to discuss the work of the ACT-Accelerator, and the financial commitments needed.



Media contact:

(10)(2e) [@who.int](#)



You are receiving this email because you are included on a WHO mail list.

If you have been forwarded this update you can [click here to subscribe](#).

Do not reply to (10)(2e) [a@campaign.who.int](#) as it is an unmonitored mailbox. Journalists may write to (10)(2e) [@who.int](#).



World Health Organization, Avenue Appia 20, 1202 Geneva 27,
Switzerland

Share

Tweet

Share

Forward

[Preferences](#) | [Unsubscribe](#)